Converting a breast cancer microarray signature into a high-throughput diagnostic test

Glas, Annuska M.; Floore, Arno; Delahaye, Leonie; Witteveen, Anke; Pover, Rob; Bakx, Niels; Lahti-Domenici, Jaana; Bruinsma, Tako J.; Warmoes, Marc O.; Bernards, René; Wessels, Lodewyk; Veer, Laura J. van ’t

doi:10.1186/1471-2164-7-278

Cited by 431 publications

(256 citation statements)

References 29 publications

Supporting

Mentioning

254

Contrasting

Unclassified

Order By: Relevance

“…79 Following an initial validation study performed in a similar population, 80 the test was commercialised. Initially it was performed using array technology on fresh-frozen tissue, 50 but since 2012 it has been available for FFPE tissue samples. 81 Currently the test is marketed by Agendia as part of the SYMPHONY profile and is performed in central laboratories located in the Netherlands and in the USA; the current list price of SYMPHONY is €2675.…”

Section: Mammaprintmentioning

confidence: 99%

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

Stein

Dunn²,

Bartlett

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 10/34/01. The contractual start date was in May 2012. The draft report began editorial review in May 2014 and was accepted for publication in September 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Background: There i...

show abstract

Section: Mammaprintmentioning

confidence: 99%

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

Stein

Dunn²,

Bartlett

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Tumour samples, RNA extraction and gene expression analysis Frozen tumour samples were processed in Agendia's laboratories (Amsterdam, the Netherlands), for RNA isolation, amplification and labelling as previously described [7,10]. Samples were available for RNA isolation if they contained at least 30% tumour cells on haematoxylin/eosin stained sections.…”

Section: Patientsmentioning

confidence: 99%

“…Tumours were classified as 70-gene good or poor prognosis-signature as described previously [6][7][8]10].…”

Section: Patientsmentioning

confidence: 99%

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

Mook

Schmidt

Viale

et al. 2008

Breast Cancer Res Treat

Self Cite

267

152

View full text Add to dashboard Cite

“…The MammaPrint assay uses microarray technology to assess a 70-gene expression profile to assess a breast cancer patient's risk of developing recurrence or distant metastases or death [4, [6][7][8]. The 70-gene expression profile was discovered by researchers at the Netherlands Cancer Institute, and is now performed and marketed by Agendia (www.agendia.com).…”

Section: Discovery Of Mammaprintmentioning

confidence: 99%

MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients

Desai¹,

Li²

2013

Handbook of Therapeutic Biomarkers in Cancer

View full text Add to dashboard Cite

Converting a breast cancer microarray signature into a high-throughput diagnostic test

Cited by 431 publications

References 29 publications

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients

Contact Info

Product

Resources

About